Overview

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

Status:
Not yet recruiting
Trial end date:
2022-09-12
Target enrollment:
Participant gender:
Summary
An Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Ferric Carboxymaltose (FCM) in Infants (0-1 year) with Iron Deficiency Anemia.
Phase:
Phase 2
Details
Lead Sponsor:
American Regent, Inc.